Under normal circumstances, KRAS is an integral part of cell function, however, once mutated, as is the case in 84% of all RAS mutations, KRAS can become the catalyst for cancerous growth, and has been explored particularly in non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer [5, 9]. Here, KRAS is linked to non-small cell lung carcinoma.